Literature DB >> 16408101

High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia.

A Sainz-Perez1, H Gary-Gouy, A Portier, F Davi, H Merle-Beral, P Galanaud, A Dalloul.   

Abstract

Chronic lymphocytic leukemia (CLL)-B-cells are quiescent differentiated cells that produce interleukin (IL)-10 and accumulate due to resistance to apoptosis. The mechanisms underlying such resistance are poorly understood. Herein we show that all CLL B-cells tested (30/30) display high mRNA and protein expression of the tumor suppressor Mda-7/IL-24, an IL-10 family member, in comparison to normal B cells. A downstream Mda-7 signaling target, p38 mitogen-activated protein kinase (MAPK) was highly phosphorylated in all CLL cells but not in normal B-cells. Mda-7 expression and p38 MAPK phosphorylation diminished in culture and the latter could be reinduced by recombinant (r)-IL-24 or LPS and Mda-7 transfection. Mda-7/IL-24 siRNA specifically inhibited p38 MAPK phosphorylation in CLL without affecting p38 MAPK, bcl2, or Lyn expression, further demonstrating the direct role of Mda-7/IL-24 in p38 MAPK activation. Both pharmacological inhibition of p38 MAPK and Mda-7 silencing augmented spontaneous apoptosis by three-fold in CLL cells cultured in autologous serum, which was reversed by LPS and r-IL-24. We established the role of p38 MAPK in CLL cell survival and demonstrated a paradoxical effect, whereby Mda-7 and IL-24, inducers of apoptosis in diverse cancer cells, promote the survival of CLL B-cells through p38 MAPK activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16408101     DOI: 10.1038/sj.leu.2404073

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Authors:  Caspar da Cunha-Bang; Carsten Utoft Niemann
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 2.  Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

Authors:  Paul B Fisher; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Pankaj Gupta; Moira Sauane; Zao-zhong Su; Steven Grant; Paul Dent; David T Curiel; Neil Senzer; John Nemunaitis
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-23       Impact factor: 4.219

3.  A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathways.

Authors:  Edward X She; Zhonglin Hao
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

4.  Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.

Authors:  Mohamed Rahmani; Mandy Mayo; Rupesh Dash; Upneet Kaur Sokhi; Igor P Dmitriev; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Journal:  Mol Pharmacol       Date:  2010-09-21       Impact factor: 4.436

5.  The p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA.

Authors:  Kristian Otkjaer; Helmut Holtmann; Tue Wenzel Kragstrup; Søren Riis Paludan; Claus Johansen; Matthias Gaestel; Knud Kragballe; Lars Iversen
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

6.  Cellular origin and pathophysiology of chronic lymphocytic leukemia.

Authors:  Marc Seifert; Ludger Sellmann; Johannes Bloehdorn; Frederik Wein; Stephan Stilgenbauer; Jan Dürig; Ralf Küppers
Journal:  J Exp Med       Date:  2012-10-22       Impact factor: 14.307

Review 7.  IL-24: a classic cytokine and/or a potential cure for cancer?

Authors:  S Kreis; D Philippidou; C Margue; I Behrmann
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

8.  CD47-retargeted oncolytic adenovirus armed with melanoma differentiation-associated gene-7/interleukin-24 suppresses in vivo leukemia cell growth.

Authors:  Gongchu Li; Hu Wu; Lianzhen Cui; Yajun Gao; Lei Chen; Xin Li; Tianxiang Liang; Xinyan Yang; Jianhong Cheng; Jingjing Luo
Journal:  Oncotarget       Date:  2015-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.